Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project.
Adult
Aged
Biomarkers
/ blood
Cardiovascular Diseases
/ blood
Female
Humans
Hyperuricemia
/ blood
Italy
/ epidemiology
Male
Middle Aged
Multicenter Studies as Topic
Observational Studies as Topic
Prognosis
Research Design
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Uric Acid
/ blood
Cardiovascular events
Cardiovascular mortality
URRAH
Uric acid
Journal
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension
ISSN: 1179-1985
Titre abrégé: High Blood Press Cardiovasc Prev
Pays: New Zealand
ID NLM: 9421087
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
14
12
2019
accepted:
04
03
2020
pubmed:
12
3
2020
medline:
24
6
2020
entrez:
12
3
2020
Statut:
ppublish
Résumé
The latest European Guidelines of Arterial Hypertension have officially introduced uric acid evaluation among the cardiovascular risk factors that should be evaluated in order to stratify patient's risk. In fact, it has been extensively evaluated and demonstrated to be an independent predictor not only of all-cause and cardiovascular mortality, but also of myocardial infraction, stroke and heart failure. Despite the large number of studies on this topic, an important open question that still need to be answered is the identification of a cardiovascular uric acid cut-off value. The actual hyperuricemia cut-off (> 6 mg/dL in women and 7 mg/dL in men) is principally based on the saturation point of uric acid but previous evidence suggests that the negative impact of cardiovascular system could occur also at lower levels. In this context, the Working Group on uric acid and CV risk of the Italian Society of Hypertension has designed the Uric acid Right for heArt Health project. The primary objective of this project is to define the level of uricemia above which the independent risk of CV disease may increase in a significantly manner. In this review we will summarize the first results obtained and describe the further planned analysis.
Identifiants
pubmed: 32157643
doi: 10.1007/s40292-020-00368-z
pii: 10.1007/s40292-020-00368-z
doi:
Substances chimiques
Biomarkers
0
Uric Acid
268B43MJ25
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
121-128Références
Int Heart J. 2014;55(1):65-70
pubmed: 24463929
Nutr Metab Cardiovasc Dis. 2014 Jul;24(7):744-50
pubmed: 24675008
Arthritis Rheum. 2012 Jan;64(1):121-9
pubmed: 22031222
Am J Physiol Cell Physiol. 2008 Nov;295(5):C1183-90
pubmed: 18784379
High Blood Press Cardiovasc Prev. 2014 Sep;21(3):189-94
pubmed: 24482065
Arch Intern Med. 2004 Jul 26;164(14):1546-51
pubmed: 15277287
J Biol Chem. 1991 May 5;266(13):8604-8
pubmed: 2022672
Circulation. 2001 Jul 17;104(3):346-51
pubmed: 11457756
Nutr Rev. 2016 Apr;74(4):259-66
pubmed: 26946251
J Am Soc Nephrol. 2005 Dec;16(12):3553-62
pubmed: 16251237
Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1186-92
pubmed: 18356554
Nutr Metab Cardiovasc Dis. 2013 Dec;23(12):1195-201
pubmed: 24099726
Metab Syndr Relat Disord. 2013 Jun;11(3):157-62
pubmed: 23360433
Am J Hypertens. 2017 Mar 1;30(3):279-285
pubmed: 28096148
Int J Cardiol. 2010 Jul 23;142(3):279-87
pubmed: 19201041
Circulation. 1997 Mar 4;95(5):1247-52
pubmed: 9054856
Eur J Heart Fail. 2014 Jan;16(1):15-24
pubmed: 23933579
Hypertension. 2000 Dec;36(6):1072-8
pubmed: 11116127
Ann Rheum Dis. 2015 Jul;74(7):1394-8
pubmed: 25667207
Int J Cardiol. 2010 Jan 21;138(2):206-9
pubmed: 18684529
Circ Heart Fail. 2009 Nov;2(6):556-62
pubmed: 19919980
J Am Soc Nephrol. 2011 Jul;22(7):1382-9
pubmed: 21719783
J Hum Hypertens. 2017 Feb;31(2):116-120
pubmed: 27465981
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46
pubmed: 23024028
Congest Heart Fail. 2011 Jan-Feb;17(1):25-30
pubmed: 21272224
Am J Cardiol. 2011 Nov 1;108(9):1272-6
pubmed: 21855838
J Clin Hypertens (Greenwich). 2019 Jul;21(7):975-983
pubmed: 31222917
Kidney Int. 1976 Jun;9(6):489-500
pubmed: 940282
PLoS Genet. 2009 Jun;5(6):e1000504
pubmed: 19503597
Stroke. 2006 Jun;37(6):1503-7
pubmed: 16675740
Monaldi Arch Chest Dis. 2019 Mar 27;89(1):
pubmed: 30968661
Expert Opin Emerg Drugs. 2018 Sep;23(3):201-209
pubmed: 30244605
BMJ Open. 2014 Jul 10;4(7):e005354
pubmed: 25011991
Eur Heart J. 2019 Jun 7;40(22):1778-1786
pubmed: 30844048
BMC Cardiovasc Disord. 2017 Sep 12;17(1):243
pubmed: 28899364
Gynecol Endocrinol. 2015;31(9):736-41
pubmed: 26376959
Heart. 2014 Jul;100(14):1085-92
pubmed: 24790069
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
J Hypertens. 2020 Mar;38(3):412-419
pubmed: 31644519
Eur Rev Med Pharmacol Sci. 2014;18(9):1295-306
pubmed: 24867507
Am J Physiol Renal Physiol. 2007 Apr;292(4):F1238-44
pubmed: 17190912
Hypertension. 2014 Nov;64(5):1102-7
pubmed: 25135183
J Hypertens. 2001 Jul;19(7):1209-15
pubmed: 11446710
J Occup Med. 1967 Dec;9(12):611-9
pubmed: 6065137
BMJ Open. 2016 Sep 08;6(9):e013774
pubmed: 27609859
Int Heart J. 2017 Aug 3;58(4):562-569
pubmed: 28701671
Curr Pharm Des. 2005;11(32):4145-51
pubmed: 16375736
Nutr Metab Cardiovasc Dis. 2018 Aug;28(8):839-846
pubmed: 29898822
Sci Rep. 2016 Jan 27;6:19520
pubmed: 26814153
Am J Cardiol. 2005 Aug 15;96(4):489-95
pubmed: 16098298
Hypertension. 2017 Feb;69(2):228-235
pubmed: 27956574
J Intern Med. 2009 Dec;266(6):558-70
pubmed: 19563390
JAMA. 2000 May 10;283(18):2404-10
pubmed: 10815083
High Blood Press Cardiovasc Prev. 2018 Jun;25(2):197-202
pubmed: 29427170
J Clin Hypertens (Greenwich). 2018 Jan;20(1):193-200
pubmed: 29171717
Hypertension. 2020 Feb;75(2):302-308
pubmed: 31813345
Am J Cardiol. 2014 Apr 1;113(7):1153-8
pubmed: 24513465